Article
Oncology
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki, Michael J. Morris
Summary: The study found that two-thirds of mCRPC patients with bone metastases received bone modifying agents (BMAs) within 180 days after initiating CDT. A greater proportion of patients without bone metastasis may warrant BMA therapy for osteoporotic fracture prevention. Some patients with bone metastasis may be able to delay BMA initiation until CRPC.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medicine, General & Internal
Edoardo Francini, Francesco Montagnani, Pier Vitale Nuzzo, Miguel Gonzalez-Velez, Nimira S. Alimohamed, Pietro Rosellini, Irene Moreno-Candilejo, Antonio Cigliola, Jaime Rubio-Perez, Francesca Crivelli, Grace K. Shaw, Li Zhang, Roberto Petrioli, Carmelo Bengala, Guido Francini, Jesus Garcia-Foncillas, Christopher J. Sweeney, Celestia S. Higano, Alan H. Bryce, Lauren C. Harshman, Richard Lee-Ying, Daniel Y. C. Heng
Summary: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases was associated with longer overall survival, especially in patients with high-volume disease.
Article
Multidisciplinary Sciences
Jeremy S. Frieling, Leticia Tordesillas, Xiomar E. Bustos, Maria Cecilia Ramello, Ryan T. Bishop, Junior E. Cianne, Sebastian A. Snedal, Tao Li, Chen Hao Lo, Janis de la Iglesia, Emiliano Roselli, Ismahene Benzaid, Xuefeng Wang, Youngchul Kim, Conor C. Lynch, Daniel Abate-Daga
Summary: We propose a combinatorial strategy using gamma 6-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL) for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). In a preclinical murine model, gamma 6 CAR-T cells targeting prostate stem cell antigen (PSCA) showed significant tumor regression, increased survival, and reduced cancer-associated bone disease. Pretreatment with ZOL enhanced the activation and antitumor efficacy of gamma 6 CAR-T cells. Our findings suggest the potential use of gamma 6 CAR-T cell therapy for mCRPC treatment.
Article
Multidisciplinary Sciences
Peter Arnold, Maria Cristina Penaloza-Ramos, Lola Adedokun, Sarah Rees, Mohamed Lockhat, Lisa Spary, Alan Watkins, Vincent Gnanapragasam, Simon J. Crabb
Summary: This study used linked datasets to explore the characteristics and outcomes of prostate cancer patients with non-metastatic castration-resistant PC. Shorter PSA doubling time was associated with quicker progression to metastases or death, while age did not show a significant association with time to metastases or death.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Amanjot Sidhu, Nabeeha Khan, Cameron Phillips, Juan Briones, Anil Kapoor, Pawel Zalewski, Neil E. Fleshner, Edward Chow, Urban Emmenegger
Summary: In this study, we found that approximately 20% of patients with metastatic castration-resistant prostate cancer (mCRPC) experience PSA flares induced by Ra223 treatment, and these flares are not closely associated with patient outcomes. Although only a few patients had PSA decreases greater than 30% after the flare, the overall survival was comparable to patients with PSA responses or non-responses.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Fanying Tang, Duo Xu, Shangqian Wang, Chen Khuan Wong, Alexander Martinez-Fundichely, Cindy J. Lee, Sandra Cohen, Jane Park, Corinne E. Hill, Kenneth Eng, Rohan Bareja, Teng Han, Eric Minwei Liu, Ann Palladino, Wei Di, Dong Gao, Wassim Abida, Shaham Beg, Loredana Puca, Maximiliano Meneses, Elisa de Stanchina, Michael F. Berger, Anuradha Gopalan, Lukas E. Dow, Juan Miguel Mosquera, Himisha Beltran, Cora N. Sternberg, Ping Chi, Howard Scher, Andrea Sboner, Yu Chen, Ekta Khurana
Summary: This study classified CRPC into different subtypes using ATAC-seq, RNA-seq, and DNA sequencing. The identified subtypes include AR-dependent, neuroendocrine, Wnt-dependent, and stem cell-like subtypes driven by AP-1 transcription factors. Transcriptomic signatures were used for patient classification, and SCL was found to be the second most common subtype of CRPC.
Article
Multidisciplinary Sciences
Yuji Hakozaki, Yuta Yamada, Taketo Kawai, Masaki Nakamura, Yuta Takeshima, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoichi Fujii, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Mayu Kashiwagi-Hakozaki, Tetsuo Ushiku, Haruki Kume
Summary: This study aimed to identify prognostic factors for cancer-specific survival in non-metastatic castration-resistant prostate cancer patients. The analysis of 82 patients revealed that PSA doubling time and time to CRPC diagnosis were significant predictors of CSS, leading to the development of a novel risk stratification.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Fred Saad, Martin Boegemann, Kazuhiro Suzuki, Neal Shore
Summary: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is characterized by rising PSA levels despite castration therapy, and patients are at risk of developing metastatic disease and cancer-related symptoms. Treatment decisions for nmCRPC patients should consider the balance between clinical benefits and potential adverse events of second-generation androgen receptor inhibitors to delay metastases and prolong survival.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Multidisciplinary Sciences
Yuji Hakozaki, Yuta Yamada, Yuta Takeshima, Satoru Taguchi, Taketo Kawai, Masaki Nakamura, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Haruki Kume
Summary: The study aimed to identify prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients and propose a new risk model. Clinical data of 102 mCRPC patients who received treatment between 2005 and 2018 at the University of Tokyo Hospital were retrospectively analyzed. The study found that low hemoglobin levels, short time to nadir PSA, and rapid PSA doubling time were independent prognostic factors for overall survival (OS).
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C. Semira, Peter Gibbs, Ben Tran, Carmel Pezaro
Summary: Bone metastases and SSEs are common in CRPC patients, yet less than half of patients receive BMAs. The use of BMAs in treatment is associated with a lower rate of SSE occurrence.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Urology & Nephrology
Soum D. Lokeshwar, Zachary Klaassen, Fred Saad
Summary: Metastatic prostate cancer is associated with high morbidity and mortality rates. Treatment of non-metastatic prostate cancer often involves androgen deprivation therapy (ADT), but many patients eventually develop castration-resistant prostate cancer (CRPC). A new stage called non-metastatic CRPC (nmCRPC) has gained attention, with three novel nonsteroidal antiandrogens (enzalutamide, apalutamide, darolutamide) showing promising results in clinical trials.
NATURE REVIEWS UROLOGY
(2021)
Article
Oncology
Cedric Pobel, Edouard Auclin, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel, Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey, Constance Thibault, Stephane Oudard
Summary: Cabazitaxel multiple rechallenges can be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer, with efficacy and manageable toxicity for those who had a good initial response to cabazitaxel.
Article
Oncology
Michael J. Grayling, Martina McMenamin, Robert Chandler, Rakesh Heer, James M. S. Wason
Summary: The augmented PSA response analysis method can improve the efficiency of prostate cancer trials in clinical practice without the need for additional data collection. This method improves the precision of estimation to a degree that is equivalent to a substantial increase in sample size. The importance of this study lies in the fact that prostate cancer trials using PSA response as a primary endpoint can be conducted with fewer participants, leading to faster completion and reduced costs.